Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16
Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16
Needham維持對Recursion Pharmaceuticals買入評級，將價格目標下調至16美元
Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $17 to $16.
Needham分析師吉爾·布盧姆(Bil Blum)維持對Recursion Pharmaceuticals (納斯達克:RXRX)的買入評級，並將目標價格從$17降至$16。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。